These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35305510)

  • 1. Generalized Anxiety Disorder: A Predictor for Poor Responsiveness to Botulinum Toxin Type A Therapy for Pediatric Migraine.
    Goenka A; Grace Yu S; Chikkannaiah M; George MC; MacDonald S; Stolfi A; Kumar G
    Pediatr Neurol; 2022 May; 130():21-27. PubMed ID: 35305510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Mathew NT; Frishberg BM; Gawel M; Dimitrova R; Gibson J; Turkel C;
    Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Botox Right for Me: When to Assess the Efficacy of the Botox Injection for Chronic Migraine in Pediatric Population.
    Goenka A; Yu SG; George MC; Chikkannaiah M; MacDonald S; Stolfi A; Kumar G
    Neuropediatrics; 2022 Oct; 53(5):344-350. PubMed ID: 35453165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: a retrospective study.
    Lin KH; Chen SP; Fuh JL; Wang YF; Wang SJ
    J Chin Med Assoc; 2014 Jan; 77(1):10-5. PubMed ID: 24269600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
    Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
    Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
    Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional Targeted Subcutaneous Injection of Botulinum Neurotoxin Type A in Refractory Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.
    Bono F; Mazza MR; Magro G; Spano G; Idone G; Laterza V; Tedeschi D; Pucci F; Gambardella A; Sarica A
    Toxins (Basel); 2023 May; 15(5):. PubMed ID: 37235358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Botulinum toxin injections for chronic migraine in adolescents - an early therapeutic option in the transition from neuropaediatrics to neurology].
    Bernhard MK; Bertsche A; Syrbe S; Weise S; Merkenschlager A
    Fortschr Neurol Psychiatr; 2014 Jan; 82(1):39-42. PubMed ID: 24446117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of escitalopram combined with botulinum toxin A in patients with generalized anxiety disorder and comorbid headache.
    Wang Y; Yang X; Ji X; Liu M; Zhou C
    Psychopharmacology (Berl); 2023 Oct; 240(10):2061-2070. PubMed ID: 37481677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum Toxin for Pediatric Migraine: A Retrospective Multisite Cohort Study.
    Horvat DE; Shields JM; Young WWC; Eye PG
    Pediatr Neurol; 2023 Oct; 147():68-71. PubMed ID: 37562172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of two different botulinum toxin type A dilutions in chronic migraineurs.
    Tereshko Y; Lettieri C; Belgrado E; Pez S; Gigli GL; Valente M
    Toxicon; 2023 May; 227():107096. PubMed ID: 36965713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
    Blumenfeld AM; Dodick DW; Silberstein SD
    Dermatol Clin; 2004 Apr; 22(2):167-75. PubMed ID: 15222577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin: A review of the mode of action in migraine.
    Do TP; Hvedstrup J; Schytz HW
    Acta Neurol Scand; 2018 May; 137(5):442-451. PubMed ID: 29405250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
    Blumenfeld A
    Headache; 2003 Sep; 43(8):853-60. PubMed ID: 12940806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type a for chronic migraine.
    Ashkenazi A
    Curr Neurol Neurosci Rep; 2010 Mar; 10(2):140-6. PubMed ID: 20425239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients.
    Schim J
    Curr Med Res Opin; 2004 Jan; 20(1):49-53. PubMed ID: 14741072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.
    Luvisetto S; Gazerani P; Cianchetti C; Pavone F
    Toxins (Basel); 2015 Sep; 7(9):3818-44. PubMed ID: 26404377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive botulinum toxin type a response is a prognosticator for migraine surgery success.
    Lee M; Monson MA; Liu MT; Reed D; Guyuron B
    Plast Reconstr Surg; 2013 Apr; 131(4):751-757. PubMed ID: 23542247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.
    Bruloy E; Sinna R; Grolleau JL; Bout-Roumazeilles A; Berard E; Chaput B
    Plast Reconstr Surg; 2019 Jan; 143(1):239-250. PubMed ID: 30589800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.